By Robert Preidt
Health Day Reporter
Friday, October 16, 2020 (HealthDay News)-Experimental COVID-19 vaccine appears to be safe and provoke an immune response in healthy people, according to preliminary results from small early-stage clinical trials.
Research on vaccines based on the inactivated whole SARS-CoV-2 virus (BBIBP-CorV) involved more than 600 Chinese volunteers aged 18-80 years. By 42 days after vaccination, all showed antibody response to the virus. researcher.
The vaccine was safe and well tolerated at all doses tested, the research leaders reported. The most common side effect was pain at the injection site. There were no serious side effects.
Survey results were released on October 15th Lancet infection journal.
Similar results have been reported from previous trials of another vaccine based on the inactivated whole SARS-CoV-2 virus. The trial was limited to people under the age of 60.
A new study found that people over the age of 60 responded more slowly to the vaccine. It took 42 days for all antibodies to be detected, compared to 28 days between the ages of 18 and 59.
Antibody levels were also lower at ages 60-80 compared to young volunteers.
“Protecting the elderly is an important goal of the success of the COVID-19 vaccine, as this age group is at high risk of serious illness, but because the immune system weakens with age, this group The effectiveness of the vaccine may be reduced. ” Co-author of the study, Xiaoming Yang, Professor of Beijing Institute of Biological Products Company Limited.
“Therefore, it is encouraging to see BBIBP-CorV elicit an antibody response in people over the age of 60, and I believe this justifies further investigation,” Yang said in a journal news release. ..
Since this study was not designed to evaluate the efficacy of the BBIBP-CorV vaccine, it is not possible to know if the antibody response it caused is strong enough to protect people from infection with the new coronavirus.
Researchers plan to test the vaccine in children under the age of 18 and teens after completing a complete analysis of data from adults.
Larisa Rudenko, a researcher at the Institute of Experimental Medicine in St. Petersburg, Russia, wrote an editorial accompanying the findings.
“Further research is needed to establish whether the inactivated SARS-CoV-2 vaccine can induce and maintain a virus-specific T cell response,” she said.